Sai Life margin drops 4.30 points QoQ despite 8.22% revenue growth
YoY profit rose 14.00%, but other income contributed 11.72% of pre-tax profit and the stock fell 1.94% in the first session.
Filed 14 May 2026, 22:59 IST · after market close · Sai Life Sciences Ltd (SAILIFE)
Key takeaways
- Standalone operating margin narrowed 4.30 percentage points QoQ as expenses grew +15.12% against revenue growth of +8.22%.
- Standalone net profit rose +14.00% YoY, helped by a 32.75% fall in interest costs and a 0.26 percentage-point lower tax rate.
- Other income rose +63.34% YoY and accounted for 11.72% of standalone profit before tax, adding to profit quality risk.
Price around the results
Revenue momentum did not carry into operating profit
Standalone revenue grew +8.22% QoQ and +4.82% YoY, but operating profit fell -6.05% sequentially as the cost base expanded faster. YoY, expenses grew only +3.17%, allowing operating profit to rise +9.25% and operating margin to improve by 1.15 percentage points.
Q4 margin fell after reaching a Q3 peak
Operating margin declined to 28.29% from 32.59% in Q3FY26 because expenses rose +15.12% against revenue growth of +8.22%. This interrupted the margin expansion seen from 23.39% in Q1FY26 to 26.55% in Q2FY26 and 32.59% in Q3FY26. The current margin remained 4.91 percentage points above the 23.38% median for 48 healthcare peers that had reported.
Lower interest costs supported the YoY profit increase
Interest expense fell -32.75% YoY and -23.57% QoQ, cushioning the effect of higher depreciation, which rose +20.74% YoY. The tax rate declined by 0.26 percentage points YoY and 0.09 percentage points QoQ. Other income represented 11.72% of pre-tax profit, so the +14.00% YoY net-profit growth was not entirely operating-led.
Management outlined a front-loaded expansion cycle
Management said it plans FY27 capex of Rs 1,100-1,300 crore, aligned with customer demand and long-term strategic opportunities. The company said about 75% of that spending is allocated to capacity expansion, including added production capacity at Unit IV in Bidar and land acquired for a greenfield site in Choutuppal. Management also said manufacturing digitisation is expected to be complete by CY2027.
The initial market reaction was milder than the stock's usual move
The stock fell -1.94% in the first session after the results, after opening with a -5.77% gap, and was up +0.12% by day five. Across the five previous result reactions, the stock rose three times and fell twice, with a median absolute move of 4.59%, making the first-session closing decline smaller than its typical move.
Q4FY26 at a glance
Standalone figures as filed with NSE — cross-checked against an independent source.
| Line item | Q4FY26 | Q3FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹594 cr | ₹549 cr | +8.22% | +4.82% |
| Other income | ₹16 cr | ₹0 cr | +10593.33% | +63.34% |
| Expenses | ₹426 cr | ₹370 cr | +15.12% | +3.17% |
| Operating profit | ₹168 cr | ₹179 cr | -6.05% | +9.25% |
| Operating margin (%) | 28.29% | 32.59% | — | — |
| Interest | ₹6 cr | ₹8 cr | -23.57% | -32.75% |
| Depreciation | ₹41 cr | ₹41 cr | +1.38% | +20.74% |
| Profit before tax | ₹137 cr | ₹130 cr | +4.89% | +13.60% |
| Tax | ₹34 cr | ₹33 cr | +4.51% | +12.41% |
| Net profit | ₹103 cr | ₹98 cr | +5.02% | +14.00% |
| EPS (₹) | ₹4.85 | ₹4.64 | +4.53% | +12.27% |
Operating margin of 28.29% compares with a Healthcare sector median of 23.38% across 48 peers that have reported Q4FY26.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -1.94% | -1.75% |
| Next session | +0.04% | — |
| 5 sessions | +0.12% | -0.01% |
| 15 sessions | +7.38% | — |
| 30 sessions | +10.95% | — |
Volume on the results session was 11.51× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- The company plans FY27 capex of ₹1,100–1,300 crore, aligned with customer demand and long-term strategic opportunities.
- The company is entering a front-loaded investment cycle aligned with long-term customer demand and strategic growth opportunities.
Expansion
- About 75% of FY27 capex is allocated to capacity expansion.
- The company is building additional production capacity at Unit IV in Bidar and has acquired land for a greenfield site in Choutuppal.
New initiatives
- The company expects manufacturing digitization to be complete by CY2027.
What to watch
- Whether operating margin recovers from 28.29% after the 4.30 percentage-point QoQ decline.
- Whether expense growth falls below the +15.12% QoQ rate against revenue growth of +8.22%.
- Progress on the planned FY27 capex of Rs 1,100-1,300 crore, including the 75% allocation to capacity expansion.